| Total JKOM knee-complaint score | In the 80 analyzed adults with mild knee symptoms, after 12 weeks at 2 g MSM daily, total JKOM was 8.1 versus 10.9 on placebo; fewer points mean fewer complaints.Final JKOM 8.1 versus 10.9; difference −2.8 (95% CI −5.5…−0.1), p=0.046 | 2/4 LowConfidence is low: in a blinded study of people with mild knee complaints, some participants were excluded from the analysis after group allocation. The difference in final scores is small and its confidence interval permits both an almost zero and a more noticeable difference; its importance for well-being has not been established. | 11 trialMethylsulfonylmethane Improves Knee Quality of Life in Participants with Mild Knee Pain: A Randomized, Double-Blind, Placebo-Controlled Trial ↗ | Japanese adults with mild knee discomfort, Kellgren–Lawrence 0–1; 88 randomized, 80 analyzed | - Methylsulfonylmethane Improves Knee Quality of Life in Participants with Mild Knee Pain: A Randomized, Double-Blind, Placebo-Controlled Trial ↗
|
|---|
| General condition on the JKOM subscale | In the same study, the JKOM general-condition measure changed by −1.3 points with MSM and −0.9 with placebo; difference in changes −0.5 points (95% CI −0.9…−0.0).Change −1.3 versus −0.9; difference −0.5 (95% CI −0.9…−0.0), p=0.032 | 2/4 LowConfidence is low: some participants were excluded from the analysis after group allocation. The difference in change in the general health measure is small and the interval is close to zero; the available description does not allow a confident judgment of its importance to a person. | 11 trialMethylsulfonylmethane Improves Knee Quality of Life in Participants with Mild Knee Pain: A Randomized, Double-Blind, Placebo-Controlled Trial ↗ | Japanese adults with mild knee discomfort; 88 randomized, 80 analyzed | - Methylsulfonylmethane Improves Knee Quality of Life in Participants with Mild Knee Pain: A Randomized, Double-Blind, Placebo-Controlled Trial ↗
|
|---|
| Pain in knee osteoarthritis | In patients with knee osteoarthritis, 6 g MSM daily over 12 weeks reduced WOMAC pain by 14.6 mm versus 7.3 mm with placebo (p=0.041).WOMAC pain change −14.6 versus −7.3 mm on a 0–100 scale; p=0.041 | Not assessedConfidence in the stated magnitude of pain reduction cannot be assessed: the available abstract reports improvement relative to placebo, but does not allow verification that −14.6 and −7.3 mm are changes over 12 weeks in the two groups, or assessment of the precision of this comparison. | 11 trialEfficacy of methylsulfonylmethane (MSM) in osteoarthritis pain of the knee: a pilot clinical trial ↗ | Adults with knee osteoarthritis; 50 randomized, 40 completed (21 MSM, 19 placebo) | - Efficacy of methylsulfonylmethane (MSM) in osteoarthritis pain of the knee: a pilot clinical trial ↗
|
|---|
| Knee function in osteoarthritis | In the same trial, WOMAC knee-function impairment fell by 15.7 mm with MSM and 8.8 mm with placebo (p=0.045).WOMAC function change −15.7 versus −8.8 mm on a 0–100 scale; p=0.045 | Not assessedConfidence in the stated magnitude of reduction in knee function impairment cannot be assessed: the available abstract reports improvement relative to placebo, but does not allow verification that −15.7 and −8.8 mm are changes over 12 weeks in the two groups, or assessment of the precision of this comparison. | 11 trialEfficacy of methylsulfonylmethane (MSM) in osteoarthritis pain of the knee: a pilot clinical trial ↗ | Adults with knee osteoarthritis; 50 randomized, 40 completed | - Efficacy of methylsulfonylmethane (MSM) in osteoarthritis pain of the knee: a pilot clinical trial ↗
|
|---|
| WOMAC knee function | In patients with confirmed knee osteoarthritis, 3.375 g MSM daily over 12 weeks improved WOMAC function by 14.6 mm versus placebo (95% CI 4.3–25.0).Between-group difference in WOMAC function change 14.6 mm; 95% CI 4.3–25.0; p=0.04 | 2/4 LowConfidence is low: participants were allocated in order of arrival, so allocation could have been predictable. The small study leaves a wide range of possible improvement; the reported interval and p-value come from different analyses. | 11 trialEfficacy of methylsulfonylmethane supplementation on osteoarthritis of the knee: a randomized controlled study ↗ | Patients aged 45–90 with clinically and radiographically confirmed knee osteoarthritis; 50 randomized | - Efficacy of methylsulfonylmethane supplementation on osteoarthritis of the knee: a randomized controlled study ↗
|
|---|
| Total WOMAC score | In the same trial, total WOMAC improved by 15.0 mm versus placebo (95% CI 5.1–24.9) over 12 weeks.Between-group difference in WOMAC total change 15.0 mm; 95% CI 5.1–24.9; p=0.03 | 2/4 LowConfidence is low: the order of participant allocation may have been predictable, and the small study does not allow the size of improvement to be determined precisely. The reported interval and p-value were obtained in different analyses. | 11 trialEfficacy of methylsulfonylmethane supplementation on osteoarthritis of the knee: a randomized controlled study ↗ | Patients aged 45–90 with confirmed knee osteoarthritis; 50 randomized | - Efficacy of methylsulfonylmethane supplementation on osteoarthritis of the knee: a randomized controlled study ↗
|
|---|
| WOMAC pain and stiffness | In the same study, separate WOMAC pain and stiffness subscales showed no convincing difference from placebo: both p=0.08.Pain 12.4 mm (95% CI 0.0–24.8), p=0.08; stiffness 27.2 mm (95% CI 8.2–46.2), p=0.08 in adjusted analysis | 2/4 LowConfidence is low: participants were allocated in order of arrival, which may have affected group composition. Estimates for pain and stiffness are imprecise; the intervals and p-values come from different analyses and cannot therefore be interpreted as a single result. | 11 trialEfficacy of methylsulfonylmethane supplementation on osteoarthritis of the knee: a randomized controlled study ↗ | Patients aged 45–90 with confirmed knee osteoarthritis; 50 randomized | - Efficacy of methylsulfonylmethane supplementation on osteoarthritis of the knee: a randomized controlled study ↗
|
|---|
| Muscle pain after a half-marathon | Among 21 half-marathon participants with completed pain ratings, the time course of muscle pain on 3 g MSM daily did not differ convincingly from placebo; at 15 minutes the difference was −19.8 mm (95% CI −43.7…+4.1).At 15 minutes, muscle-pain difference −19.8 mm (95% CI −43.7…+4.1); overall time×group not significant | 3/4 ModerateConfidence is moderate: the blinded study included few runners, and the confidence interval for pain at 15 minutes permits both a substantial reduction and a small increase in pain. The article has an inconsistency in group sizes; a non-significant overall interaction alone does not prove absence of an effect. | 11 trialEffects of Methylsulfonylmethane (MSM) on exercise-induced oxidative stress, muscle damage, and pain following a half-marathon: a double-blind, randomized, placebo-controlled trial ↗ | 22 randomized; 21 assessed muscle pain (11 MSM, 10 placebo) | - Effects of Methylsulfonylmethane (MSM) on exercise-induced oxidative stress, muscle damage, and pain following a half-marathon: a double-blind, randomized, placebo-controlled trial ↗
|
|---|
| Facial wrinkle visibility | In a small trial of 20 women, facial wrinkle ratings after 16 weeks were lower with 3 g MSM daily than placebo (p<0.05); the article gives no exact between-group effect size.Expert visual wrinkle rating: direction favors MSM, p<0.05; numerical contrast/CI unpublished | Not assessedThe certainty of the wrinkle result cannot yet be assessed: the available abstract does not describe the allocation method or expert blinding, and does not report the magnitude of the between-group difference. Therefore, it is unknown how much the result depends on features of the comparison and how large the possible effect is. | 11 trialBeauty from within: Oral administration of a sulfur-containing supplement methylsulfonylmethane improves signs of skin ageing ↗ | Women aged 35–59 with signs of skin aging; 20 completed (11 MSM, 9 placebo) | - Beauty from within: Oral administration of a sulfur-containing supplement methylsulfonylmethane improves signs of skin ageing ↗
|
|---|